NO991483L - Insulin C-peptider - Google Patents

Insulin C-peptider

Info

Publication number
NO991483L
NO991483L NO991483A NO991483A NO991483L NO 991483 L NO991483 L NO 991483L NO 991483 A NO991483 A NO 991483A NO 991483 A NO991483 A NO 991483A NO 991483 L NO991483 L NO 991483L
Authority
NO
Norway
Prior art keywords
peptide
fragment
peptides
atpase activity
stimulate
Prior art date
Application number
NO991483A
Other languages
English (en)
Norwegian (no)
Other versions
NO991483D0 (no
Inventor
John Wahren
Bo-Lennart Johansson
Rnvall Hans J
Original Assignee
Creative Peptides Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab
Publication of NO991483D0 publication Critical patent/NO991483D0/no
Publication of NO991483L publication Critical patent/NO991483L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO991483A 1996-09-27 1999-03-26 Insulin C-peptider NO991483L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus
PCT/GB1997/002627 WO1998013384A1 (en) 1996-09-27 1997-09-26 Insulin c-peptides

Publications (2)

Publication Number Publication Date
NO991483D0 NO991483D0 (no) 1999-03-26
NO991483L true NO991483L (no) 1999-05-18

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991483A NO991483L (no) 1996-09-27 1999-03-26 Insulin C-peptider

Country Status (24)

Country Link
US (1) US6610649B2 (de)
EP (1) EP0938503B1 (de)
JP (1) JP2001500893A (de)
KR (1) KR20000048643A (de)
AT (1) ATE347562T1 (de)
AU (1) AU741901B2 (de)
BG (1) BG103362A (de)
BR (1) BR9711573A (de)
CA (1) CA2266416C (de)
CZ (1) CZ108599A3 (de)
DE (1) DE69737065T2 (de)
DK (1) DK0938503T3 (de)
ES (1) ES2278394T3 (de)
HU (1) HUP0000432A3 (de)
IL (1) IL129143A0 (de)
IS (1) IS5008A (de)
NO (1) NO991483L (de)
NZ (1) NZ335231A (de)
PL (1) PL332494A1 (de)
RU (1) RU2206336C2 (de)
SE (1) SE520392C2 (de)
SK (1) SK39499A3 (de)
TR (1) TR199900694T2 (de)
WO (1) WO1998013384A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
AU2004204727B8 (en) * 2003-01-06 2006-11-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
WO2005117937A2 (en) * 2004-05-27 2005-12-15 Essential Skincare Llc Alpha-1- acid glycoprotein for the treatment of diabetes
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
EP2054437A2 (de) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
WO2009046847A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of peptide ll-37 as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
NZ603399A (en) 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2683393B1 (de) 2011-02-11 2018-04-11 The Regents of The University of Michigan Tripeptidzusammensetzungen und deren verwendung zur behandlung von diabetes
EP2780030A4 (de) 2011-11-17 2015-11-18 Cebix Ab Pegyliertes c-peptid
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
SG11201906939XA (en) 2017-02-06 2019-08-27 Resiliun B V Interaction between c-peptides and elastin receptor, a model for understanding vascular disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166913B (de) * 1972-05-15 1975-06-28
JPS5210872B2 (de) 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
IL66611A0 (en) 1981-08-27 1982-12-31 Lilly Co Eli Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
DK0640101T3 (da) 1992-04-13 2000-05-15 Oklahoma Med Res Found Fremgangsmåder og reagenser til diagnosticering af autoantistoffer
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
ES2130629T3 (es) 1994-07-08 1999-07-01 Dartmouth College Compuestos peptidicos de proinsulina para detectar y tratar la diabetes tipo i.
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
CA2249742A1 (en) 1996-03-15 1997-09-18 Steven G. Reed Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Also Published As

Publication number Publication date
BG103362A (en) 2000-05-31
BR9711573A (pt) 2000-01-18
IL129143A0 (en) 2000-02-17
ATE347562T1 (de) 2006-12-15
PL332494A1 (en) 1999-09-13
HUP0000432A3 (en) 2000-10-30
SE520392C2 (sv) 2003-07-01
IS5008A (is) 1999-03-23
DE69737065T2 (de) 2007-06-28
SK39499A3 (en) 1999-10-08
US20020107175A1 (en) 2002-08-08
ES2278394T3 (es) 2007-08-01
WO1998013384A1 (en) 1998-04-02
RU2206336C2 (ru) 2003-06-20
AU741901B2 (en) 2001-12-13
JP2001500893A (ja) 2001-01-23
EP0938503A1 (de) 1999-09-01
DK0938503T3 (da) 2007-04-10
NZ335231A (en) 2000-11-24
SE9603533D0 (sv) 1996-09-27
TR199900694T2 (xx) 1999-06-21
CZ108599A3 (cs) 1999-08-11
NO991483D0 (no) 1999-03-26
SE9603533L (sv) 1998-03-28
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
AU4391597A (en) 1998-04-17
KR20000048643A (ko) 2000-07-25
US6610649B2 (en) 2003-08-26
EP0938503B1 (de) 2006-12-06
CA2266416A1 (en) 1998-04-02
HUP0000432A2 (hu) 2000-08-28

Similar Documents

Publication Publication Date Title
NO991483L (no) Insulin C-peptider
Wagstaff et al. Molecular characterisation of endogenous snake venom metalloproteinase inhibitors
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
GB9519275D0 (en) Substances and their therapeutic use
ATE497390T1 (de) Neue therapeutische verwendung von smr-1 peptide
GB9422175D0 (en) Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
EP0981352A4 (de) Verfahren zur eosinophilveringerung und zusammensetzungen dafür
NO974260L (no) Nye definerte enzymblandinger for oppnåelse av celler og behandling av sår
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
DE69712182T2 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
WO1997040073A3 (de) BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN
BR0308040A (pt) Composições farmacêuticas e cosméticas compreendendo plgf-1
EP1598420A3 (de) Pharmazeutische Zusammensetzungen und deren Verwendung insbesondere in der Behandlung von neurodegenerativen Krankheiten
Sobolewski et al. Binding of the basic fibroblast growth factor (bFGF) by soluble components of human umbilical cord.
NO20023914D0 (no) Preparater for anvendelse ved regulering av Parkin- genaktiviteten
DK1340507T3 (da) Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser
WO2005005668A3 (en) Diagnosis and treatment methods related to aging (8a)
WO2002062996A1 (fr) Nouveau peptide physiologiquement actif et utilisation de ce peptide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application